Table 1. Frequency of Fas-, ceramide-,... | American Society of Hematology

Table 1.

Frequency of Fas-, ceramide-, and PDN-resistant subjects in normal controls and different patient groups

Subjects	Total n	Fas-Resistant^*		Ceramide-Resistant^*		PDN-Resistant^*
Subjects	Total n	n	(%)	n	(%)	n	(%)
Total controls^†	75	2	(3)	2	(3)	3	(4)
ALD controls^‡	20	1	(5)	0	(0)	0	(0)
ALD relatives	24	20	(83)^1-153,^1-155	11	(46)^1-153,^1-155	0	(0)
MAS controls^1-154	15	0	(0)	1	(7)	1	(7)
MAS families	17	8	(47)^1-153#	2	(14)	2	(14)

Subjects	Total n	Fas-Resistant^*		Ceramide-Resistant^*		PDN-Resistant^*
Subjects	Total n	n	(%)	n	(%)	n	(%)
Total controls^†	75	2	(3)	2	(3)	3	(4)
ALD controls^‡	20	1	(5)	0	(0)	0	(0)
ALD relatives	24	20	(83)^1-153,^1-155	11	(46)^1-153,^1-155	0	(0)
MAS controls^1-154	15	0	(0)	1	(7)	1	(7)
MAS families	17	8	(47)^1-153#	2	(14)	2	(14)

Number (n) and percentage (%) of subjects displaying a specific cell survival higher than the mean + 2 SD displayed by total controls.

Total controls run in this study.

Controls run in the experiments testing ALD relatives.

Significantly different from total controls (P < .0001, Fisher exact test).

Significantly different from ALD controls (P < .0001 for Fas and P = .0007 for ceramide, Fisher exact test).

Controls run in the experiments testing MAS families.

#Significantly different from MAS controls (P = .0042, Fisher exact test).